| Předmět: |
|
| Zdroj: |
Vaccine Weekly; 5/3/2024, p2914-2914, 1p |
| Abstrakt: |
Navigo Proteins GmbH has filed a patent application for a binding protein that specifically targets the spike protein of the SARS-CoV-2 virus, which causes COVID-19. This binding protein has a strong affinity for the spike protein and can be used in diagnostic and therapeutic applications. It can also be combined with other binding proteins to form multimers. The patent application also includes an affinity separation matrix for purifying the spike protein or its domains. This invention aims to support research and development in the field of COVID-19 diagnostics and therapeutics. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
